Abstract:Significance: Chronic wounds affect 10.5 million (up 2.3 million from the 2014 update) of U.S. Medicare beneficiaries. Chronic wounds impact the quality of life of nearly 2.5% of the total population of the United States. This fraction is larger in the elderly. These wounds can lead to a range of complications and health care costs. Given the aging population, the continued threat of diabetes and obesity worldwide, and the persistent problem of infection, it is expected that chronic wounds will continue to be a substantial clinical, social, and economic challenge. Disparities in the prevalence and management of chronic wounds exist, with underserved communities and marginalized populations often facing greater challenges in accessing quality wound care. These disparities exacerbate the public health burden. Recent Advances: U.S. Centers for Medicare and Medicaid Services had proposed revision of its local coverage determination limiting the use of skin substitute grafts/cellular and/or tissue-based products for the treatment of diabetic foot ulcers and venous leg ulcers in the U.S. Medicare population. In response to the comment phase, this proposal has been put on hold. The U.S. Food and Drug Administration (FDA) has renewed its focus on addressing nonhealing chronic wounds and has outlined efforts to address identified barriers to product development for nonhealing chronic wounds. The new approach places emphasis on engaging key wound healing stakeholders, including academia, professional associations, patient groups, reimbursement organizations, and industry. Finally, recent advances demonstrating that wounds closed by current FDA definition of wound closure may remain functionally open because of deficiencies in restoration of barrier function warrant revisiting the wound closure endpoint. Such "closed" wounds that are functionally open, also known as invisible wounds, are likely to be associated with high wound recurrence. Future Directions: Addressing the public health problem of chronic wounds will require a multifaceted approach that includes prevention, improved wound care management, and addressing the underlying risk factors.

Current Status and Future of Skin Substitutes for Chronic Wound Healing

Skin Substitutes and Wound Healing: Current Status and Challenges

The role of skin substitutes in the management of chronic cutaneous wounds

Comparison of Skin Substitutes for Acute and Chronic Wound Management

Skin substitutes for acute and chronic wound healing: an updated review

The Combined Use of Negative-Pressure Wound Therapy and Dermal Substitutes for Tissue Repair and Regeneration

Bioengineering Skin Substitutes for Wound Management—Perspectives and Challenges

Trends in the Treatment of Chronic Wounds

Updates on Recent Clinical Assessment of Commercial Chronic Wound Care Products

Emerging Trends in Therapeutic Algorithm of Chronic Wound Healers: Recent Advances in Drug Delivery Systems, Concepts-to-Clinical Application and Future Prospects.

Tissue Engineered Skin and Wound Healing: Current Strategies and Future Directions

Cellular therapeutics and immunotherapies in wound healing – on the pulse of time?

Current and Future Perspectives on Skin Tissue Engineering: Key Features of Biomedical Research, Translational Assessment, and Clinical Application

Engineered Skin Substitutes in Dermatologic Surgery: A Systematic Review

Development of pro‐angiogenic skin substitutes for wound healing

Human Wound and Its Burden: Updated 2022 Compendium of Estimates

Advances in the Research of Negative-Pressure Wound Therapy Inducing the Vascularization of Dermal Substitute

Regenerative Medicine Approaches for Skin Wound Healing: from Allografts to Engineered Skin Substitutes

Bioengineering skin using mechanisms of regeneration and repair

Recent advances in molecular mechanisms of skin wound healing and its treatments

A Concise Review on Tissue Engineered Artificial Skin Grafts for Chronic Wound Treatment: Can We Reconstruct Functional Skin Tissue In Vitro?